JY
EGRX

Jeff Yass’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Jeff Yass’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-10,400
Closed -$58.2K – 13309
2024
Q2 		$58.2K Buy
+10,400
New +$45.3K ﹤0.01% 11343
2022
Q1 		– Sell
-4,900
Closed -$250K – 14188
2021
Q4 		$250K Sell
4,900
-18,700
-79% -$969K ﹤0.01% 10945
2021
Q3 		$1.32M Buy
+23,600
New +$1.16M ﹤0.01% 6837
2020
Q4 		– Sell
-17,100
Closed -$726K – 11862
2020
Q3 		$726K Sell
17,100
-2,700
-14% -$118K ﹤0.01% 6885
2020
Q2 		$950K Buy
19,800
+2,600
+15% +$130K ﹤0.01% 6050
2020
Q1 		$791K Sell
17,200
-67,500
-80% -$3.39M ﹤0.01% 5918
2019
Q4 		$5.09M Buy
84,700
+72,600
+600% +$4.33M ﹤0.01% 2946
2019
Q3 		$684K Sell
12,100
-36,800
-75% -$2.07M ﹤0.01% 6584
2019
Q2 		$2.72M Buy
48,900
+25,100
+105% +$1.31M ﹤0.01% 3609
2019
Q1 		$1.2M Sell
23,800
-24,900
-51% -$1.11M ﹤0.01% 4661
2018
Q4 		$1.96M Sell
48,700
-105,500
-68% -$5.44M ﹤0.01% 3550
2018
Q3 		$10.7M Buy
154,200
+40,200
+35% +$3.05M ﹤0.01% 1857
2018
Q2 		$8.63M Buy
114,000
+46,100
+68% +$2.9M ﹤0.01% 2091
2018
Q1 		$3.58M Buy
67,900
+10,300
+18% +$599K ﹤0.01% 2980
2017
Q4 		$3.08M Buy
57,600
+23,900
+71% +$1.33M ﹤0.01% 3200
2017
Q3 		$2.01M Sell
33,700
-56,700
-63% -$3.43M ﹤0.01% 3905
2017
Q2 		$7.13M Sell
90,400
-17,800
-16% -$1.46M ﹤0.01% 2002
2017
Q1 		$8.97M Sell
108,200
-132,900
-55% -$9.88M ﹤0.01% 1724
2016
Q4 		$19.1M Buy
241,100
+46,400
+24% +$3.37M 0.01% 1086
2016
Q3 		$13.6M Buy
194,700
+115,400
+146% +$6.39M 0.01% 1295
2016
Q2 		$3.08M Sell
79,300
-55,400
-41% -$2.31M ﹤0.01% 2896
2016
Q1 		$5.46M Buy
134,700
+117,000
+661% +$7.42M ﹤0.01% 2195
2015
Q4 		$1.57M Sell
17,700
-29,500
-63% -$2.33M ﹤0.01% 4536
2015
Q3 		$3.49M Buy
47,200
+33,400
+242% +$2.78M ﹤0.01% 3235
2015
Q2 		$1.12M Buy
+13,800
New +$899K ﹤0.01% 5979

Other funds holding EGRX

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Jeff Yass's EGRX Position: Q2 2024 in Review

Jeff Yass sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q2 2024, closing a stake of 11,087 shares — an estimated $48.3K sold.

Jeff Yass first reported a position in EGRX in Q1 2015 and held it in 24 quarters. The position peaked at $2.93M in Q4 2015. 75 funds tracked by Wall St. Rank hold EGRX as of Q2 2024.

  • Jeff Yass reported no remaining Eagle Pharmaceuticals, Inc. position as of Q2 2024 after selling out during the quarter.
  • Jeff Yass sold 11,087 Eagle Pharmaceuticals, Inc. shares in Q2 2024, an estimated $48.3K.
  • Jeff Yass first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2015 and held it in 24 quarters.
  • Jeff Yass's Eagle Pharmaceuticals, Inc. position peaked at $2.93M in Q4 2015.
  • 75 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q2 2024.

Based on Susquehanna International Group's 13F filing for Q2 2024, filed 15 Aug 2024.